{"nctId":"NCT02609659","briefTitle":"Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Low-Dose Ribavirin QD in Subjects With Genotype 1a Chronic Hepatitis C Virus Infection","startDateStruct":{"date":"2015-10-28","type":"ACTUAL"},"conditions":["Hepatitis C Virus (HCV)"],"count":105,"armGroups":[{"label":"3-DAA + RBV 600 mg","type":"EXPERIMENTAL","interventionNames":["Drug: ombitasvir/paritaprevir/ritonavir and dasabuvir","Drug: ribavirin"]}],"interventions":[{"name":"ombitasvir/paritaprevir/ritonavir and dasabuvir","otherNames":["Viekira Pak","paritaprevir also known as ABT-450","ombitasvir also known as ABT-267","dasabuvir also known as ABT-333"]},{"name":"ribavirin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Chronic hepatitis C virus (HCV) infection\n* Non-cirrhotic subjects\n* Screening laboratory results showing HCV Genotype 1a (HCV GT1a) infection\n* HCV treatment-naïve or if treated previously, only with interferon (IFN) or pegylated interferon (pegINF) with or without ribavirin (RBV)\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women\n* Positive for hepatitis B surface antigen (HBsAg) or anti-human immunodeficiency virus antibody (HIV Ab)\n* HCV genotype of any subtype other than GT1a or unable to subtype\n* Prior or current use of any investigational or commercially available anti-HCV agents other than IFN, pegIFN or RBV. Subjects with previous participation in trials of investigational direct-acting antiviral agents (DAAs) may be enrolled if they can produce documentation that they received only placebo.\n* Current enrollment in another interventional clinical study or receipt of any investigational product within 6 weeks prior to study drug administration.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)","description":"SVR12 was defined as plasma hepatitis C virus ribonucleic acid (HCV RNA) level less than the lower limit of quantification \\[\\<LLOQ\\]) 12 weeks after the last dose of study drug. The primary efficacy endpoint was noninferiority of the percentage of participants who achieved SVR12 in participants in the treatment arm 3-DAA + RBV 600 mg) for 12 weeks compared with the historical control rate for subjects treated with 3-DAA + weight-based RBV for 12 weeks.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"89.5","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Hemoglobin < 10 g/dL During Treatment","description":"The percentage of participants with hemoglobin \\<10 g/dL during treatment is provided.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Mean Change in Hemoglobin Values From Baseline to End of Treatment","description":"The mean change in hemoglobin (g/L) from baseline to each study visit and to the final treatment visit (up to 12 weeks) is provided.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.4","spread":"8.17"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.9","spread":"9.37"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.2","spread":"9.85"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.4","spread":"10.06"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.1","spread":"9.90"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With On-treatment Virologic Failure","description":"On-treatment virologic failure was defined as confirmed HCV RNA ≥ LLOQ after HCV RNA \\< LLOQ during treatment; confirmed increase of \\> 1 log(subscript)10(subscript) IU/mL above the lowest value post-baseline in HCV RNA during treatment; or all on-treatment values of HCV RNA ≥ LLOQ with at least 6 weeks of treatment.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Post-treatment Relapse","description":"Post-treatment relapse was defined as confirmed HCV RNA ≥ LLOQ between the end of treatment and 12 weeks after the last dose of study drug, excluding reinfection, among participants who completed treatment with HCV RNA levels \\< LLOQ at the end of treatment.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":105},"commonTop":["FATIGUE","HEADACHE","INSOMNIA","NAUSEA","DIARRHOEA"]}}}